· Amgen on üks suurimaid biofarmaatsia firmasid ·EPOGEN® (epoetin alfa) ·Aranesp® (Darbepoetin alfa) ·Enbrel® (etanercept) ·NEUPOGEN® (Filgrastim) ·Neulasta® (pegfilgrastim) ·Nplate® (romiplostim) ·Prolia® (denosumab) e XGEVA® ·Sensipar® (cinacalcet) ·Vectibix® (panitumumab) ·EPOGEN® (epoetin alfa) - erütropoietiin, mis toodetakse rakukultuuri poolt ·Aranesp® (Darbepoetin alfa)- erineb endogeensest erütropoietiinist selle poolest, et sisaldab kahte lisa N-terminaalset oligosahhariidi ahelat. · stimuleerib erütropoieesi ja seda kasutatakse aneemia raviks, mis on seotud kroonilise neerupuudulikkusega ja kemoteraapiaga. NEUPOGEN® ja Neulasta® · Mõlemad on GCSF (granulocyte colony-stimulating factor) analoogid
Haematology, 125, 24-30. -43- 15) Barlogie B, Desican R, Eddelmon P. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients, Blood (2001) 98: 492-494. 16) Heinz L et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations, the Hematology Journal (2002) 3: 121-130 17) Richardson P et al. A phase 2 study of bortezomib in relapsed, refractory myeloma, N Engl J Med (2003) 348: 2609-17 18) Jagannath s. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma, British Journal of Haematology (2004) 127: 165-172 19) Harousseau J-L. Bortezomib in multiple myeloma: treatment approach and outcomes, EJC Supplements (2004) vol 2.6, 12-17
annaabi.ee 
